Findings reveal CXCR3 deficiency mitigates retinal ganglion cell loss in glaucoma, suggesting a new therapeutic strategy.
CXCL10/CXCR3 signaling is a key mediator of RGC loss in glaucoma. Targeting this pathway, along with its upregulated C3/C3aR axis, represents a promising IOP-independent therapeutic strategy for glaucoma.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: